EMA granted clearance to advancebelrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in ...

The results of the GALAXIES Lung-02 study reported at the ESMO congress in Barcelona showed that the drug – added to GSK's PD-1 inhibitor Jemperli (dostarlimab) – achieved a higher objective ...

The FDA has cleared GSK's PD-1 inhibitor Jemperli as a treatment ... The approval is based on the RUBY trial, which showed that Jemperli (dostarlimab) given with carboplatin and paclitaxel ...

Finally, the assay can be used with Merck’s Keytruda (pembrolizumab) and GSK’s Jemperli (dostarlimab) across solid tumors ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), following a string of exits by companies including Pfizer, UCB, WuXi AppTec and ...

We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry’s largest trade group, the Biotechnology Innovation Organization ...

Teva Pharmaceutical Industries Ltd. ADR-1.50% $19.72B ...

GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Service Income and Other Operating Revenue for the year ending 31-Mar-2024.For the quarter ended 30-09-2024, ...

24 Jul, 2018 11 Sep, 2018 1:1 For every 1 share held; Holder will receive 1 bonus shares. 28 Sep, 1994 02 Jan, 1995 1:1 For every 1 share held; Holder will receive 1 bonus shares. 23 Jun, 1980-1:3 ...

Involves transaction of at least 0.5% of the listed shares of a company. What was Glaxosmithkline Pharmaceuticals Ltd share price previously? Glaxosmithkline Pharmaceuticals Ltd share price was ...